discover
develop
transform
market
It's in Our DNA
We discover, develop, and market transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Using state-of-the-art analytical equipment, automated specimen processing, and advanced reporting applications.
A Resource to Help you Deliver Optimal Patient Care
Designed specifically for healthcare professionals who are dedicated to making better, more informed clinical decisions and serving patients across the sequence of patient care.
patients & partners first
innovative solutions
exceed expectations
Industry Leading Testing
Genetix iQ Approach is Changing Infectious Disease Diagnostics
- Faster Turnaround Time
- Higher Accuracy
- Precise Treatment Recommendations
- Improves Antibiotic Stewardship
Syndromic Approach
A symptom-driven diagnostic method that combines a broad grouping of probable pathogenic causes into a single, rapid test.
Faster Results
We help healthcare providers deliver proper treatment and reduce patient hospital stays by providing fast and accurate pathogen identification.
Molecular Solutions
Our team leads the industry in infectious disease diagnostics and provides molecular solutions with many benefits.
Empower Providers
With a same day turnaround for most of our tests, healthcare providers & clinicians can make vital decisions faster and more accurately.
Our Commitment
We are committed to improving the quality of life for everyone, everywhere, and every day.
Better Results
Our syndromic approach increases the probability of identifying a pathogen in patients with symptoms of an infectious disease.
Interactive Antibiotic Guide for Molecular UTI Panel
Introducing intelligent diagnostic solutions for antibiotic stewardship in partnership with the Sanford Guide. Antibiotic Stewardship involves making responsible decisions on when and how to prescribe antibotic therapy.
Intelligent Antibiotic Reference Guide
Urinary tract infections are among the most common types of illnesses among all ages. Each year, around 150 million people are affected by symptomatic or asymptomatic urinary tract infections, which could present serious health issues.
SARS-CoV-2 FAQ
What do I need to know about COVID-19 testing?
The COVID-19 (SARS-CoV-2) test with iQ Genetix utilizing a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab.
What are the symptoms of being infected with the SARS-CoV-2 Virus?
There is limited information available to characterize the spectrum of clinical illness associated with COVID-19 but it likely spreads to others when a person shows signs or symptoms. Based on what is known about the virus that causes COVID-19, signs and symptoms may appear any time from 2 to 14 days after exposure to the virus. Based on preliminary data, the median incubation period is approximately 4 days. Most patients with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing).
Please visit: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
How accurate is the iQ Genetix PCR test?
The analytic sensitivity of the iQ Genetix PCR COVID-19 test was determined to be 100% in detecting known amounts of SARS-CoV-2 RNA with no cross reactivity to other known respiratory pathogens. A Not Detected (negative) test result for this test means that SARS-CoV-2 RNA was not present in the specimen above the manufacturer recommended cutoff value.
An interpretation indicating “Not Detected” does not rule out the possibility of COVID-19 and should not be used as the sole basis for treatment or patient management decisions. If COVID-19 is still suspected, based on exposure history together with other clinical findings, re-testing should be considered in consultation with public health authorities. Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making a final diagnosis and patient management decisions.
How soon after exposure can we detect the virus using nasal swabs?
Studies have been conducted on symptomatic patients; thus, it is unknown the exact exposure date for both symptomatic and asymptomatic patients. Studies show that asymptomatic patients begin shedding later after exposure* then symptomatic patients and then shed for a longer period of time. Additionally, asymptomatic patients also produce less antibodies.
When will we get the results?
You will receive the test results from iQ Genetix within 24-48 hours from the time of receipt at the laboratory.
Get in Touch
- 10640 Page Avenue Suite 230, Fairfax, VA 22030
- Lab: (703) 891-1919
- Fax: (703) 891-1877
- cs@genetixiq.com
